PRIMAXIN IV (Page 7 of 7)
PRINCIPAL DISPLAY PANEL 250 mg Vial Label
NDC 0006-3514-58
250
PRIMAXIN® I.V.
(IMIPENEM AND CILASTATIN FOR INJECTION)
IMIPENEM 250 mg (Anhydrous Equivalent)
CILASTATIN EQUIVALENT 250 mg
CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
NOT FOR DIRECT INFUSION
Rx only
250 mg
Merck Sharp & Dohme Corp., a subsidiary ofMERCK & CO., INC., Whitehouse Station, NJ 08889, USA
3514
PRINCIPAL DISPLAY PANEL 500 mg Vial Label
NDC 0006-3516-59
500
PRIMAXIN® I.V.
(IMIPENEM AND CILASTATIN FOR INJECTION)
Each vial contains 500 mg imipenem (equivalent to 530 mg
imipenem monohydrate), 500 mg cilastatin (equivalent to 531 mg
cilastatin sodium), and 20 mg sodium bicarbonate (used as a buffer).
CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
NOT FOR DIRECT INFUSION
Rx only 500 mg
PRINCIPAL DISPLAY PANEL — 500 mg Vial Package
1 PACKAGE (25 VIALS)
NDC 0006-3516-59
500
PRIMAXIN® I.V.
(IMIPENEM AND CILASTATIN FOR INJECTION)
Not to be divided.
Each vial contains 500 mg imipenem (equivalent to 530 mg imipenem monohydrate), 500 mg cilastatin
(equivalent to 531 mg cilastatin sodium), and 20 mg sodium bicarbonate (used as a buffer).
CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY / NOT FOR DIRECT INFUSION
For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See
accompanying circular. Color changes in solution from colorless to
yellow do not affect potency. Store dry material below 25ºC.
Rx only
Merck Sharp & Dohme LLC
Rahway, NJ 07065, USA
Copyright © 2022 Merck & Co., Inc.
Rahway, NJ, USA, and its affiliates.All rights reserved.
PRINCIPAL DISPLAY PANEL — Single-Dose ADD-Vantage Vial 250 mg
NDC 0006-3551-58
Single-dose ADD-Vantage® vial
250
PRIMAXIN® I.V.
(IMIPENEM AND CILASTATIN FOR INJECTION)
IMIPENEM 250 mg (Anhydrous Equivalent)
CILASTATIN EQUIVALENT 250 mg
CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
NOT FOR DIRECT INFUSION
PRIMAXIN is a registered trademark of Merck Sharp & Dohme Corp.
ADD-Vantage is a registered trademark of ABBOTT LABORATORIES, Inc.
9960800
For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See accompanying circular.
Store dry material below 25°C.
After constitution as directed, the solution maintains satisfactory potency for 4 hours at room temperature.
Consult accompanying INSTRUCTIONS FOR USE.
Use only with ADD-Vantage® Diluent Containers.
Rx only
250 mg | No. 3551
Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC.Whitehouse Station, NJ 08889, USA
PRINCIPAL DISPLAY PANEL — Single-Dose ADD-Vantage Vial 500 mg
NDC 0006-3552-59
Single-dose ADD-Vantage® vial
500
PRIMAXIN® I.V.
(IMIPENEM AND CILASTATIN FOR INJECTION)
IMIPENEM 500 mg (Anhydrous Equivalent)
CILASTATIN EQUIVALENT 500 mg
CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
NOT FOR DIRECT INFUSION
PRIMAXIN is a registered trademark of Merck Sharp & Dohme Corp.
ADD-Vantage is a registered trademark of ABBOTT LABORATORIES, Inc.
9940700
For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See accompanying circular.
Store dry material below 25°C.
After constitution as directed, the solution maintains satisfactory potency for 4 hours at room temperature.
Consult accompanying INSTRUCTIONS FOR USE.
Use only with ADD-Vantage® Diluent Containers.
Rx only
500 mg | No. 3552
Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC.Whitehouse Station, NJ 08889, USA
PRIMAXIN IV imipenem and cilastatin sodium injection, powder, for solution | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
PRIMAXIN IV imipenem and cilastatin sodium injection, powder, for solution | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
PRIMAXIN IV imipenem and cilastatin sodium injection, powder, for solution | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
PRIMAXIN IV imipenem and cilastatin sodium injection, powder, for solution | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
Labeler — Merck Sharp & Dohme LLC (118446553) |
Revised: 12/2023 Merck Sharp & Dohme LLC
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.